Inc. (KOSDAQ: 208340), will participate in the KABSP-SF 2020 held at the Hilton
SF Airport on January 11 in San Francisco,California.
As one of active members
of KABSP, PharmAbcine sponsors the KABSP-SF 2020 Symposium and Dr. Jin-San Yoo
(CEO) will present at the symposium on
January 11, 2020. During the
presentation, Dr. Jin-San Yoo will highlight recent remarks of company’s
clinical and pre-clinical pipelines and its achievements.
The detail of
presentation are as follows:
Date: January 11, 2020
Time: 11:30 AM PST
Track: Embassy Suites
Venue: Hilton SF Airport, San Francisco
is looking to attain a talent pool for prospective candidates by holding an
on-site job interview at the KASBP-SF.
(Korean American Society in Biotech and pharmaceuticals) is a non-profit
organization for Korean-American professionals in life-sciences, biotech and
pharmaceutical fields. The purpose of KASBP is to promote strategic partnership
among the members in the life science related fields such that it can
help the members to achieve drug discovery and drug development and exchange
in information and technologies among Korean and US companies. During
symposium, KASBP also holds a panel discussion with invited experts to share up-to-date
information and their professional expertise, and posts employment
for job seekers and employers.
more information about the KASBP-SF 2020 Symposium, please visit the website: https://www.kasbpsf.org/
About PharmAbcine Inc.
is a clinical-stage biotech company focusing on the development of fully human
antibody (mAb) therapeutics, especially reputed for leading the
next-generation multi-specific antibodies. This multi-specific antibody
technology can be achieved through our in-house novel technology
namely DIG-Body, PIG-Body and TIG-Body. Using innovative discovery technology
and excellent human resources, we provide a number of
immunotherapeutics for indications in immuno-oncology, immunology and
HuPhage library and innovative selection system are priceless proprietary
assets. Additionally, our well-established 3G expression system
helped concrete our stupendous reputation in the field of biopharma industry by
allowing us to achieve the reinforcement and reproducibility of high
antibody production. On the basis of its highly maintained, advanced technical
systems, we provide high quality antibody generation services.
high standards antibodies have allowed us to be actively involved in
co-development with our partners and we are willing to expand co-development
to other potential partners.
the collaboration with SAMSUNG MEDICAL CENTER, we have more than 300
patients-derived cancer stem cell libraries and an animal model
evaluating internal pipeline development.